Published in final edited form as:

J Assoc Nurses AIDS Care. 2020 ; 31(1): 51–59. doi:10.1097/JNC.0000000000000077.

Obesity impacts the association of bioelectrical impedance phase angle with mortality in people living with HIV

Viola Cogliandro, MD [Physician],

Ospedale Monza San Gerardo, Monza, Italy.

Donna Yester, MS, RD [Clinical Dietitian],

The 1917 Clinic, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Andrew O. Westfall, MS [Biostatistician],

School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.

James L. Raper, DSN, CRNP, JD [Professor],

School of Medicine and School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Michael S. Saag, MD [Professor],

Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

German Henostroza, MD [Associate Professor],

Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

E. Turner Overton, MD [Professor],

Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Amanda L. Willig, PhD, RD [Assistant Professor]

Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Abstract

Bioelectrical impedance analysis phase angle (BIA-PA) is a valid indicator of mortality risk in people living with HIV (PLWH); however, it is not known if BIA-PA is valid for PLWH who are overweight or obese. We assessed whether BIA-PA differentially predicted mortality by body mass index category in participants receiving clinical care at a single site between 2000-2012. Change in BIA-PA from the highest versus last available phase angle was assessed using multivariate logistic regression models. 890 participants were included in the final analyses, with 102 deaths recorded during the study period. Decline in BIA-PA was associated with mortality in underweight and normal weight participants, but not in overweight or obese participants. Additional investigation is

Corresponding Author: Amanda L. Willig; awillig@uabmc.edu.

Disclosures

The authors report no real or perceived vested interests that relate to this article that could be construed as a conflict of interest

warranted to determine the appropriate clinical BIA-PA equations and parameters to identify overweight and obese patients with elevated mortality risk.

Keywords

HIV; bioelectrical impedance; phase angle; mortality; obesity

Introduction

The introduction of combination antiretroviral therapy (cART) for people living with HIV (PLWH) was accompanied by a shift from wide-spread undernutrition and wasting to overnutrition and obesity (Crum-Cianflone, Tejjidor, Medina, Barahona, & Ganesan, 2008; Guehi et al., 2016; Kim et al., 2012; McCormick et al., 2014; Smit et al., 2002; Tate et al., 2012). In the pre-cART era, loss of body weight and wasting of lean body mass were considered symptoms of advanced stages of HIV infection, and an independent factor contributing to disease progression and mortality (Schwenk et al., 2000). Biomarkers of health status were needed to track wasting and related health outcomes; thus bioelectrical impedance analysis was used to assess changes in nutritional status and body composition before and after cART initiation.

Bioelectrical impedance analysis is a noninvasive technique that measures electrical resistance and reactance to calculate a person's phase angle (BIA-PA) and estimate total body fat. The results reflect not only the body cell mass, but also the cell membrane function related to water distribution between the extra- and intracellular spaces (Barbosa-Silva & Barros, 2005; Kyle, Bosaeus, De Lorenzo, Deurenberg, Elia, Gomez, et al., 2004). There is a strong association between cellular health and BIA-PA, such that a high BIA-PA indicates intact cell membranes and body cell mass, while low BIA-PA suggests poor selective permeability of the cell membrane and poor cellular energy storage (Kyle, Genton, Slosman, & Pichard, 2001; Ott et al., 1995). Prior to the availability of cART, BIA-PA decline was a validated, recognized prognostic marker for mortality in the setting of untreated HIV infection; low values were associated with a rapid clinical progression and shorter survival time, regardless of the degree of immunodeficiency and viremia (Ott et al., 1995). The correlation between declines in BIA-PA and mortality has similarly been observed in other diseases, including frailty (Mullie et al., 2018), cancer (lung, colorectal and pancreatic; Gupta, Lammersfeld, et al., 2004; Gupta et al., 2009; Gupta, Lis, et al., 2004; Norman et al., 2010), cirrhosis (Selberg & Selberg, 2002), and hemodialysis for end stage renal disease (Di Iorio, Scalfi, Terracciano, & Bellizzi, 2004). In the cART era, the prognostic ability of BIA-PA has been confirmed, suggesting that the decrease in BIA-PA is not only a consequence of body cell mass and wasting syndrome, but a reflection of systemic reaction to infection (Schwenk et al., 1999; Schwenk et al., 2000).

BIA-PA is currently used by health care professionals to monitor health status and mortality risk of PLWH; however, BIA measures are inaccurate at extremely low or high body weights (Kyle, Bosaeus, De Lorenzo, Deurenberg, Elia, Gomez, et al., 2004; Kyle, Bosaeus, De Lorenzo, Deurenberg, Elia, Manuel Gomez, et al., 2004), and the increasing obesity (body

mass index; BMI ≥ 30 kg/m²) prevalence among people living with HIV could alter the prognostic capabilities of PA change. Moreover, cART has radically changed from the beginning of the HIV epidemic. Current cART regimens have less toxicity on metabolic parameters, yet most studies on the relationship between PA and cART include only early cART regimens (Schwenk et al., 1999; Schwenk et al., 2000). Analysis of the utility of BIA-PA in current clinical practice is necessary to inform twenty-first century clinical care of PLWH. The aim of this study is to evaluate the association of change in PA with mortality in a recent cohort of PLWH who experience greater prevalence of overweight and obesity compared to cohorts in previous investigations.

Methods

Data were obtained from the University of Alabama at Birmingham (UAB) 1917 HIV/AIDS Clinic Cohort Observational Database Project (UAB 1917 Clinic Cohort). This cohort forms an on-going prospective clinical study that has collected detailed sociodemographic, psychosocial, and clinical data from individuals diagnosed with HIV since 1988. For this study of BIA-PA, we conducted a retrospective analysis of Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) data collected at the 1917 Clinic between 2000-2012. During the study period, the Clinic used a locally programmed electronic medical record (EMR) containing detailed provider encounter notes, imported all laboratory values from the central UAB laboratory, and required electronic prescriptions for all medications. The EMR and database were quality controlled, with all provider notes reviewed to ensure appropriate data capture regarding diagnoses and medications (including start and stop dates for prescriptions). New and ongoing diagnoses are recorded in patients' active problem lists, while resolved diagnoses discontinued by the provider remain part of the patients' EMR after removal from the active problem list. The UAB Institutional Review Board (IRB) approved this retrospective study nested in the UAB 1917 Clinic Cohort.

Participants

All patients seen at the UAB 1917 HIV Clinic between January 1, 2000 and June 30, 2012 were eligible. Inclusion criteria were: (a) ≥ 19 years of age, (b) diagnosis of HIV, (c) at least two primary care visits at the UAB 1917 Clinic at which BIA-PA was performed, and (d) height, weight, plasma HIV RNA, and CD4 count measured within the study period. All data were acquired through electronic queries (MS SQL®) of the UAB 1917 Clinic database.

Study variables

Body composition: Height to the nearest 0.1 cm and weight to the nearest 0.1kg were obtained from the EMR and used to calculate BMI (weight [kg] / height [m²]). The following categories were used to classify patients by BMI: underweight <18.5 kg / m², normal weight = 18.5 to 24.9 kg / m², overweight = 25 to 29.9 kg / m², and obese ≥ 30 kg / m². All BIA measurements were performed or confirmed by the same registered dietitian at the time of the patient's regularly scheduled clinic appointment. Tetrapolar BIA was completed with a bioelectrical impedance analyzer (RJL Systems Inc.; Cinton Township, MI), while participants lay supine on an examination table with legs and arms apart.

Electrodes were placed on the right side of the body near the wrist and ankle joints of the hand and foot. A 50-kHz excitation current was initiated and used to compute resistance (R; sum of geometrical in-phase vectors) and reactance (X; capacitance or sum of out-phase vectors). Resistance and reactance were used to estimate body fat mass, fat-free mass, and total body water. Phase angle (BIA-PA) was computed using the following equation: $BIA-PA = (\text{resistance/reactance}) \times (180/3.14159153)$.

Covariates: We extracted demographic and laboratory information from the EMR including age, sex, self-reported race/ethnicity, CD4+ T-cell count, plasma HIV RNA, antiretroviral regimen (use of protease inhibitors), insurance status (none, private, public), history of substance abuse (yes/no), and year the patient started care at the 1917 Clinic. As patients with advanced-stage infection would be expected to have greater mortality risk, history of opportunistic infections was also abstracted to identify those staged as Centers for Disease Control (CDC) Class C (CDC, 1992).

Mortality: Patients were classified according to mortality (yes/no) during the study period. Year of death was abstracted from the EMR, and the BIA-PA value at the closest date prior to death was recorded. For patients who were not deceased at end of the study period, the last available BIA-PA value was recorded.

Statistical Analysis

Chi-square, Kruskal-Wallis, and one-way analysis of variance tests were used to analyze differences between BMI categories related to descriptive characteristics and BIA parameters (resistance, reactance, phase angle, fat mass percent, fat-free mass percent).

Change in BIA-PA was computed as highest BIA-PA – last BIA-PA. Reconstitution of health and immune function is associated with initiation of cART and an increase in BIA-PA; thus, we used the highest BIA-PA reported for a patient as a more accurate indicator of cellular status following reconstitution of health. Univariate logistic regression models were run for the total sample and by BMI category to evaluate the association of BIA-PA decline with mortality. Univariate modeling of covariates was also conducted to identify factors associated with mortality in the total sample. Multivariate logistic regression was utilized to model the impact of change in BIA-PA on mortality risk in the total sample and by BMI category after controlling for highest BIA-PA measurement, insurance type, CDC “C” classification, history of protease inhibitor use, and CD4+ T cell count. All data were analyzed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) with a significance level of $p < 0.05$.

Results

Characteristics of the study population by BMI category are presented in Table 1. There were 1,149 patients who met age, height, and weight criteria. Of those, 213 patients were excluded for having less than two BIA-PA measurements, and 46 deceased patients were excluded who did not have a BIA measurement within the year prior to death, leaving a final sample size of 890 participants. At the time of highest BIA-PA measurement, participants were ages 41.9 ± 9.6 years, with no difference among groups. Approximately 73% of

participants were male and 51% self-reported as racial/ethnic minorities. All but five non-White participants self-identified as Black, with the remaining five self-reporting Hispanic ethnicity with multiracial or Black race; therefore, we were not powered to analyze these five individuals separately and included them in the “minority” racial group. A greater percentage of females and minorities were observed in both the underweight and obese groups ($p < .01$). Obese participants were more likely to have private health insurance and higher CD4+ T-cell count compared to other groups (all at $p < .01$). There were no group differences in viral load, history of substance abuse, year of initiating care at the clinic, or disease staging of CDC “C” classification. By 2012, 102 (11.5%) deaths had been recorded, with significantly more deaths occurring in the underweight ($n = 13$; 26%) group compared to normal weight ($n = 62$; 15.2%), overweight ($n = 18$; 6.9%), and obese ($n = 9$; 5.3%) groups ($p = .01$).

Bioelectrical impedance analysis.

Results of bioelectrical impedance analysis were significantly different by BMI category at the time of highest and last BIA-PA measurement (Table 2). At the time of highest BIA-PA, underweight participants had significantly greater resistance and reactance measures and a lower BIA-PA compared to all other groups ($p < .01$). Obese participants had a lower measure of resistance compared to normal weight/overweight participants, a higher percentage of body fat mass (33.2%), and a lower percent lean mass (66.8%) compared to all other groups (all at $p < .01$). There were no significant group differences in change between the highest and last BIA; however, underweight participants were the only group to experience a median decline in resistance (−15.5).

Mortality risk.

In univariate models, a decline in BIA-PA was associated with increased mortality risk in the total sample [odds ratio (OR) 1.8; 95% confidence interval (CI) 1.5-2.2], in underweight (OR 5.8, 95% CI 1.8-19.0) and normal weight (OR 2.2, 95% CI 1.6-3.1) participants (all at $p < .01$; Table 3). BIA-PA decline was not associated with mortality risk in overweight or obese participants.

In multivariable regression models (Table 3), BIA-PA decline remained significantly associated with increased mortality in the total sample (OR 2.2, 95% CI 1.6-2.9; $p < .01$) and among underweight (OR 6.6, 95% CI 1.2-34.8; $p = .02$) and normal weight (OR 2.2, 95% CI 1.5-3.4; $p < .01$) groups. There was no association of BIA-PA decline with mortality among overweight or obese participants. A higher initial BIA-PA was associated with decreased mortality risk in the total sample (OR 0.6, 95% CI 0.4-0.7; $p < .01$), normal weight (OR 0.6, 95% CI 0.4-0.8; $p < .01$), and overweight (OR 0.6, 95% CI 0.3-0.9; $p = .04$) groups, but not among underweight or obese participants.

Additional covariates were associated with mortality risk in the total sample and normal weight participants. Increased mortality was observed with public versus private insurance, with a CDC “C” disease classification and with a CD4+ T-cell count < 200 cells/ μ L at time of highest BIA-PA. Greater change in CD4+ T-cell count was associated with decreased mortality among the total sample, normal weight, and overweight participants.

Discussion

This is one of the first studies to investigate the association of BIA-PA with mortality in HIV in a population that includes significant numbers of overweight/obese individuals. Our results reveal that in the current era of cART, BIA-PA remains a valuable prognostic indicator of mortality risk in underweight and normal weight PLWH; however, BIA-PA is not predictive of mortality in overweight or obese PLWH. These findings are in contrast to previous studies of PLWH in the pre- or early-cART eras, which identified an inverse association between mortality and BIA-PA regardless of body weight (Ott et al., 1995; Schwenk et al., 1999; Schwenk et al., 2000). Those data were collected prior to 2000 and typically included participants with a mean BMI in the normal weight range and mean CD4+ values < 350 cells/ μ L. The present investigation measured BIA-PA over a decade later than previous studies, in a population where almost half of participants (48%) were classified as overweight/obese and had CD4+ values > 350 cells/ μ L. Thus, the present study may more accurately reflect the prognostic capability of BIA-PA for present-day HIV treatment.

Currently, BIA-PA is assessed in PLWH when an individual is new to HIV care, is underweight, experiences unplanned weight loss, or has a low CD4+ percent. BIA-PA measurements are determined primarily by biological factors, such as age and sex; however, obesity is associated with elevated fat mass and variations in hydration status that can alter the accuracy of bioelectrical impedance assessment (Bosy-Westphal et al., 2006; Dittmar, 2003). BIA-PA is a less reliable measure of body compartment mass once BMI surpasses 34 kg/m², at which point errors in prediction are greater (Kyle, Bosaeus, De Lorenzo, Deurenberg, Elia, Gomez, et al., 2004; Kyle, Bosaeus, De Lorenzo, Deurenberg, Elia, Manuel Gomez, et al., 2004). Additionally, BIA-PA increases with BMI until a BMI of 40 kg/m² is reached, at which lower BIA-PA is observed (Bosy-Westphal et al., 2006); however, our sample size was underpowered to analyze separate categories within obesity (BMI $\geq$ 30 kg/m²). Despite the use of an HIV-specific equation for BIA-PA measurement, additional work may be required to develop equations that consider the impact of both HIV and obesity on tissue hydration status and cellular mass. Bioelectrical impedance measures are more accurate in overweight individuals; however, we did not detect an association of BIA-PA with mortality in this study sample. Interestingly, we previously observed higher than expected levels of adiposity in overweight PLWH (Willig, Heath, Muhammad, & Overton, 2015; Willig et al., 2017); PLWH who are overweight per BMI but have very high levels of body fat may experience similar measurement error issues observed with extreme obesity. It is also possible that overweight and obese individuals with HIV maintain adequate cellular mass for survival even when general cellular degradation results in a declining BIA-PA. The factors contributing to a lower mortality risk with declining BIA-PA in this group require additional investigation.

Although phase angle was not associated with mortality in overweight/obese PLWH, BIA-PA remained an important indicator of mortality risk in underweight and normal weight individuals. A decline in phase angle represents a breakdown of cellular membranes that may be detrimental to overall health. Generally, a phase angle > 5.0 degrees in women and > 6.0 degrees in men is considered healthy (Kyle et al., 2001). The majority (79%) of our

study participants were male, with a median BIA-PA > 6.0; however, median BIA-PA ranged from only 5.5 to 6.9 across BMI categories. Overall, these values are significantly lower than those reported in HIV-uninfected groups. Barbosa-Silva and colleagues reported that while BIA-PA did decline with age, the median score for men was 6.2 to 8.0 and 5.6 to 7.0 for women (Barbosa-Silva, Barros, Wang, Heymsfield, & Pierson, 2005). They observed a median BIA-PA < 7.0 only in men older than 60 years of age, while the median age in our study sample was only 42 years. In another sample of HIV-uninfected participants, Kumar et al. likewise reported a mean BIA-PA of 7.4 in men and 7.1 in women (Kumar, Dutt, Hemraj, Bhat, & Manipadybhima, 2012). Collectively, this suggests that the BIA-PA of PLWH at all body sizes remains lower than that observed in healthy, HIV-uninfected groups. Further investigations of factors that contribute to degradation of cellular membranes in the current era of HIV treatment are warranted.

BIA-PA can be used clinically to identify and monitor PLWH who have controlled viremia yet are experiencing decreased cellular integrity (i.e., nutritional decline) and mortality risk. Those individuals who present with a low BIA-PA can receive more intensive medical nutrition therapy with a focus on foods and nutritional supplementation to improve body protein stores and decrease mortality risk ("Erratum," 2018; Viertel, Bock, Reich, Loser, & Plauth, 2018; Willig, Wright, & Galvin, 2018). The results of the current study affirm that BIA-PA assessed in the clinical setting to identify patients in need of focused medical nutrition therapy remains valid for underweight and normal weight PLWH; however, alternative approaches may be needed to identify overweight and obese individuals with declining health who are in need of more intensive interventions focused on maintaining body protein stores. The development of these tools will be necessary as the prevalence of obesity among PLWH in low, middle, and high-income countries continues to increase (Crum-Cianflone et al., 2008; Hidalgo et al., 2018; Semu et al., 2016; Tate et al., 2012).

These findings should be placed in the context of certain limitations. While participants received an annual BIA-PA screen during the study period, those who were at high risk for malnutrition (CD4% < 15%, previously documented low BIA-PA) were more likely to complete additional BIA-PA assessments. Thus, the study sample may include a greater proportion of participants with medical complications compared to studies of healthy populations. Consideration of diagnosed infections and comorbidities in this cohort did not alter the association of BIA-PA with mortality; however, the overall number of patients with diagnoses such as cirrhosis, cancer, and acute infections was low, limiting our ability to explicate the contributions of these individual diagnoses to BIA-PA levels. The evaluations were conducted as part of routine clinical visits, thus some participants may not have adhered to guidelines for avoiding moderate/vigorous exercise or excessive fluid consumption several hours prior to measurement. Significantly less mortality was observed in overweight/obese groups compared to underweight/normal weight participants; however, the study was powered to detect the association of BIA-PA with mortality in all groups. Additionally, this investigation focused on mortality and does not exclude the prognostic value of BIA-PA in risk for other metabolic diseases, including cardiovascular, renal, and cancer diagnoses.

In conclusion, BIA-PA remains an independent predictor of mortality among underweight/normal weight PLWH. It is less clear whether BIA-PA has prognostic value for mortality risk among overweight/obese PLWH, which is concerning given the rapid increase in body weight among HIV-infected groups. Besides evaluating underweight PLWH, current triggers for BIA-PA assessment (new to care, low CD4%, unplanned weight loss) do not consider the impact of being overweight or obese on the interpretation of BIA-PA results. Adjusted BIA-PA equations that simultaneously consider HIV infection and excess adiposity are needed. Additional study of appropriate prognostic indicators for cellular membrane degradation and mortality risk in this increasing subset of PLWH is greatly needed to improve clinical care in HIV treatment.

Acknowledgments

We thank the UAB Research Informatics Service Center for assistance with data abstraction, and patients at the 1917 clinic for their on-going partnership in clinical research. This study was supported by the UAB Center for AIDS Research (NIAID P30-AI27767), the Mary Fisher CARE Fund, the UAB Center for Outcomes and Effectiveness Research and Education, UAB Nutrition Obesity Research Center (NIDDK # P30DK056336), and the UAB Center for Exercise Medicine. Dr. Willig received additional support from the UAB Center for Clinical and Translational Sciences (NCATS 5TL1TR001418).

REFERENCES

- Barbosa-Silva MC, & Barros AJ (2005). Bioelectrical impedance analysis in clinical practice: a new perspective on its use beyond body composition equations. *Current Opinion in Clinical Nutrition and Metabolic Care*, 8(3), 311–317. 10.1097/01.mco.0000165011.69943.39 [PubMed: 15809535]
- Barbosa-Silva MC, Barros AJ, Wang J, Heymsfield SB, & Pierson RN Jr. (2005). Bioelectrical impedance analysis: Population reference values for phase angle by age and sex. *The American Journal of Clinical Nutrition*, 82(1), 49–52. 10.1093/ajcn/82.1.49 [PubMed: 16002799]
- Bosy-Westphal A, Danielzik S, Dorhofer RP, Later W, Wiese S, & Muller MJ (2006). Phase angle from bioelectrical impedance analysis: Population reference values by age, sex, and body mass index. *Journal of Parenteral and Enteral Nutrition*, 30(4), 309–316. 10.1177/0148607106030004309 [PubMed: 16804128]
- Centers for Disease Control Prevention (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Recommendations and reports: Morbidity and mortality weekly report, 41(RR-17), 1–19. Retrieved from <https://www.cdc.gov/MMWR/preview/MMWRhtml/00018871.htm>
- Crum-Cianflone N, Tejjidor R, Medina S, Barahona I, & Ganesan A (2008). Obesity among patients with HIV: The latest epidemic. *AIDS Patient Care and STDs*, 22(12), 925–930. 10.1089/apc.2008.0082 [PubMed: 19072098]
- Di Iorio BR, Scalfi L, Terracciano V, & Bellizzi V (2004). A systematic evaluation of bioelectrical impedance measurement after hemodialysis session. *Kidney International*, 65(6), 2435–2440. 10.1111/j.1523-1755.2004.00660.x [PubMed: 15149357]
- Dittmar M (2003). Reliability and variability of bioimpedance measures in normal adults: Effects of age, gender, and body mass. *American Journal of Physical Anthropology*, 122(4), 361–370. 10.1002/ajpa.10301 [PubMed: 14614757]
- Erratum. (2018). *Journal of the Academy of Nutrition and Dietetics*, 118(5), 949 10.1016/j.jand.2018.03.023 [PubMed: 29703345]
- Guehi C, Badje A, Gabillard D, Ouattara E, Koule SO, Moh R, Danel C (2016). High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial. *AIDS Research and Therapy*, 13, 12 10.1186/s12981-016-0094-y [PubMed: 26925155]
- Gupta D, Lammersfeld CA, Burrows JL, Dahlk SL, Vashi PG, Grutsch JF, Lis CG (2004). Bioelectrical impedance phase angle in clinical practice: Implications for prognosis in advanced

- colorectal cancer. *The American Journal of Clinical Nutrition*, 80(6), 1634–1638. 10.1093/ajcn/80.6.1634 [PubMed: 15585779]
- Gupta D, Lammersfeld CA, Vashi PG, King J, Dahlk SL, Grutsch JF, & Lis CG (2009). Bioelectrical impedance phase angle in clinical practice: Implications for prognosis in stage IIIB and IV non-small cell lung cancer. *BMC Cancer*, 9, 37. 10.1186/1471-2407-9-37 [PubMed: 19175932]
- Gupta D, Lis CG, Dahlk SL, Vashi PG, Grutsch JF, & Lammersfeld CA (2004). Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. *The British Journal of Nutrition*, 92(6), 957–962. 10.1079/BJN20041292 [PubMed: 15613258]
- Hidalgo JA; Florez A; Agurto C; Pinedo Y; Ayarza R; Rodriguez L; La Rosa A; Gutierrez R (2018). Metabolic and cardiovascular comorbidities among clinically stable HIV patients on long-term ARV therapy in five ambulatory clinics in Lima-Callao, Peru. *Open AIDS Journal*, 12, 126–135. 10.2174/1874613601812010126 [PubMed: 30450147]
- Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, . . . Willig JH (2012). Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. *Journal of Acquired Immune Deficiency Syndromes*, 61(5), 600–605. 10.1097/QAI.0b013e31827303d5 [PubMed: 23023101]
- Kumar S, Dutt A, Hemraj S, Bhat S, & Manipadybhima B (2012). Phase Angle Measurement in Healthy Human Subjects through Bio-Impedance Analysis. *Iranian Journal of Basic Medical Sciences*, 15(6), 1180–1184. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646229/pdf/IJBMS-15-1180.pdf> [PubMed: 23653848]
- Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, . . . Composition of the, E. W. G. (2004). Bioelectrical impedance analysis--part I: Review of principles and methods. *Clinical Nutrition*, 23(5), 1226–1243. 10.1016/j.clnu.2004.06.004 [PubMed: 15380917]
- Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J, . . . Espen. (2004). Bioelectrical impedance analysis-part II: Utilization in clinical practice. *Clinical Nutrition*, 23(6), 1430–1453. 10.1016/j.clnu.2004.09.012 [PubMed: 15556267]
- Kyle UG, Genton L, Slosman DO, & Pichard C (2001). Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98 years. *Nutrition*, 17(7-8), 534–541. 10.1016/S0899-9007(01)00555-X [PubMed: 11448570]
- McCormick CL, Francis AM, Iliffe K, Webb H, Douch CJ, Pakianathan M, & Macallan DC (2014). Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention. *Frontiers in Immunology*, 5, 507. 10.3389/fimmu.2014.00507 [PubMed: 25431572]
- Mullie L, Obrand A, Bendayan M, Trnkus A, Ouimet MC, Moss E, . . . Afilalo J (2018). Phase angle as a biomarker for frailty and postoperative mortality: The BICS study. *Journal of the American Heart Association*, 7(17), e008721. 10.1161/JAHA.118.008721 [PubMed: 30371163]
- Norman K, Stobaus N, Zocher D, Bosy-Westphal A, Szramek A, Scheufele R, . . . Pirlich M (2010). Cutoff percentiles of bioelectrical phase angle predict functionality, quality of life, and mortality in patients with cancer. *The American Journal of Clinical Nutrition*, 92(3), 612–619. 10.3945/ajcn.2010.29215 [PubMed: 20631202]
- Ott M, Fischer H, Polat H, Helm EB, Frenz M, Caspary WF, & Lembcke B (1995). Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 9(1), 20–25. Retrieved from https://journals.lww.com/jaids/Abstract/1995/05010/Bioelectrical_Impedance_Analysis_as_a_Predictor_of.3.aspx [PubMed: 7712230]
- Schwenk A, Beisenherz A, Kremer G, Diehl V, Salzberger B, & Fatkenheuer G (1999). Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. *The American Journal of Clinical Nutrition*, 70(5), 867–873. 10.1093/ajcn/70.5.867 [PubMed: 10539747]
- Schwenk A, Beisenherz A, Romer K, Kremer G, Salzberger B, & Elia M (2000). Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. *The American Journal of Clinical Nutrition*, 72(2), 496–501. 10.1093/ajcn/72.2.496 [PubMed: 10919947]

- Selberg O, & Selberg D (2002). Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. *European Journal of Applied Physiology*, 86(6), 509–516. 10.1007/s00421-001-0570-4 [PubMed: 11944099]
- Semu H, Zack RM, Liu E, Hertzmark E, Spiegelman D, Sztam K, ... Fawzi W (2016). Prevalence and risk factors for overweight and obesity among HIV-infected adults in Dar es Salaam, Tanzania. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, 512–521. 10.1177/2325957414542574 [PubMed: 25146972]
- Smit E, Skolasky RL, Dobs AS, Calhoun BC, Visscher BR, Palella FJ, & Jacobson LP (2002). Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. *American Journal of Epidemiology*, 156(3), 211–218. 10.1093/aje/kwf039 [PubMed: 12142255]
- Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, ... Mugavero MJ (2012). HIV infection and obesity: Where did all the wasting go? *Antiviral Therapy*, 17(7), 1281–1289. 10.3851/IMP2348 [PubMed: 22951353]
- Viertel M, Bock C, Reich M, Loser S, & Plauth M (2018). Performance of CT-based low skeletal muscle index, low mean muscle attenuation, and bioelectric impedance derived low phase angle in the detection of an increased risk of nutrition related mortality. *Clinical Nutrition*. 10.1016/j.clnu.2018.10.018
- Willig A, Wright L, & Galvin TA (2018). Practice paper of the Academy of Nutrition and Dietetics: Nutrition intervention and Human Immunodeficiency Virus Infection. *Journal of the Academy of Nutrition and Dietetics*, 118(3), 486–498. 10.1016/j.jand.2017.12.007 [PubMed: 29477186]
- Willig AL, Heath SL, Muhammad J, & Overton ET (2015). Low physical function is observed among adults living with HIV regardless of age group or body composition. *Antiviral Therapy*, 20(Supplement 1), A38–A39. Retrieved from <https://www.intmedpress.com/serveFile.cfm?sUID=79530527-9ec4-45ab-87b5-310ce3c5f61d>
- Willig AL, Kramer PA, Chacko BK, Darley-Usmar VM, Heath SL, & Overton ET (2017). Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected women. *Redox Biology*, 12, 648–656. 10.1016/j.redox.2017.04.005 [PubMed: 28395172]

Key Considerations

- Bioelectrical impedance analysis phase angle (BIA-PA) is a validated predictor of cellular health and mortality risk in normal weight people living with HIV on early ART regimens.
- In the current era of cART, BIA-PA remains a valuable prognostic indicator of mortality risk in underweight and normal weight adults with HIV, and can be used to identify patients who need more intensive medical nutrition therapy.
- BIA-PA does not predict mortality risk in overweight or obese adults with HIV.
- As the prevalence of overweight and obesity continues to increase globally among adults with HIV, new approaches for estimating cellular integrity and mortality risk in the context of controlled viremia are needed.

Patient characteristics ($M \pm SD$ or n [%]) stratified by body mass index (BMI) category at time of highest bioelectrical impedance analysis measurement

Table 1.

Variable	Total ^a <i>N</i> = 890	Underweight (BMI <18.5 kg / m ²) <i>n</i> = 50	Normal weight (BMI 18.5-24.9 kg / m ²) <i>n</i> = 409	Overweight (BMI 25-29.9 kg / m ²) <i>n</i> = 261	Obesity (BMI ≥30 kg / m ²) <i>n</i> = 170	<i>p</i> value ^b
Age	41.9 ± 9.6	41.2 ± 11.3	41.3 ± 9.6	42.4 ± 9.5	42.5 ± 9.0	.33
Sex						
Male	706 (79.3%)	35 (5.0%)	345 (48.7%)	213 (30.2%)	113 (16.0%)	<.01
Female	184 (20.7%)	15 (8.2%)	64 (34.8%)	48 (26.1%)	57 (30.9%)	
Race						
White	430 (48.7%)	17 (3.9%)	225 (52.3%)	131 (30.5%)	57 (13.3%)	<.01
Minority ^c	453 (51.3%)	32 (7.1%)	183 (40.4%)	128 (28.2%)	110 (24.3%)	
Health Insurance						
Uninsured	245 (28.2%)	12 (4.9%)	114 (46.5%)	76 (31.0%)	43 (17.6%)	<.01
Public	320 (36.8%)	29 (9.0%)	151 (47.2%)	86 (26.9%)	54 (16.9%)	
Private	304 (35.0%)	7 (2.3%)	133 (43.8%)	95 (31.3%)	69 (22.7%)	
Sexual Risk Factor						
Heterosexual	345 (38.8%)	23 (6.7%)	139 (40.3%)	95 (27.5%)	88 (25.5%)	<.01
MSM ^d	510 (57.3%)	23 (4.5%)	252 (49.4%)	159 (31.2%)	76 (14.9%)	
Other/Unknown	35 (3.9%)	4 (11.4%)	18 (51.4%)	7 (20.0%)	6 (17.1%)	
Substance Abuse (ever)	256 (28.8%)	14 (28.0%)	130 (31.8%)	73 (27.9%)	39 (22.9%)	.19
CD4 count (cells/μl)						
0-199/μl	288 (33.6%)	27 (9.4%)	137 (47.6%)	78 (27.1%)	46 (15.9%)	<.01
200 – 350/μl	186 (21.7%)	7 (3.8%)	88 (47.3%)	62 (33.3%)	29 (15.6%)	
> 350/μl	383 (44.7%)	15 (3.9%)	166 (43.3%)	117 (30.6%)	85 (22.2%)	
log ₁₀ plasma HIV RNA (copies/mL)	2.9 ± 1.4	3.4 ± 1.7	3.0 ± 1.4	2.7 ± 1.3	2.9 ± 1.4	.08
Viral Load < 200 copies/ml	424 (49.3%)	22 (44.9%)	182 (46.1%)	141 (54.7%)	79 (50.0%)	.17
CDC “C” diagnosis	355 (39.9%)	26 (52.0%)	171 (41.8%)	98 (37.6%)	60 (35.3%)	.12
Year Starting Care						
2000 to 2004	331 (37.2%)	23 (6.9%)	168 (50.8%)	91 (27.5%)	49 (14.8%)	.10
2005 to 2008	308 (34.6%)	15 (4.8%)	132 (42.9%)	97 (31.5%)	64 (20.8%)	

Variable	Total ^a N = 890	Underweight (BMI <18.5 kg / m ²) n = 50	Normal weight (BMI 18.5-24.9 kg / m ²) n = 409	Overweight (BMI 25-29.9 kg / m ²) n = 261	Obesity (BMI ≥30 kg / m ²) n = 170	^b p value
2009 to 2012	251 (28.2%)	12 (4.8%)	109 (43.4%)	73 (29.1%)	57 (22.7%)	
Use of PI regimen (yes)	546 (61.4%)	24 (48.0%)	255 (62.4%)	166 (63.6%)	101 (59.4%)	.19
Deaths at last observation period	102 (11.5%)	13 (26.0%)	62 (15.2%)	18 (6.9%)	9 (5.3%)	.01

^aMissing values: race = 7; insurance = 21; CD4 = 33; Viral Load = 30

^bp value based on Kruskal-Wallis or chi-square test

^cFive Minority participants identified as Hispanic ethnicity with multiracial or Black race; the remaining participants identified as Black

^dMSM = men who have sex with men; RNA = ribonucleic acid ; PI = Protease Inhibitor

Table 2.

Measurements associated with bioelectrical impedance analysis (BIA) phase angle measurement, stratified by body mass index (BMI) category

Variable	Total <i>N</i> = 890	Underweight (BMI < 18.5) <i>n</i> = 50	Normal weight (BMI 18.5-24.9) <i>n</i> = 409	Overweight (BMI 25-29.9) <i>n</i> = 261	Obesity (BMI ≥ 30) <i>n</i> = 170
<i>At time of highest BIA:^a</i>					
Height (cm)	175.3 (170.2,182.9)	175.3 (165.1,180.3)	177.8 (170.2,182.9)	176.5 (170.2,182.9)	174.6 (166.4,182.9)*
Weight (kg)	76.8 (67.3,89.5)	52.0 (46.4,56.8)	69.5 (63.6,74.5)	84.1 (78.2,90.5)	102.3 (94.5,112.7)**
Body mass index	24.7 (21.8,28.6)	17.1 (16.2,17.9)	22.1 (21.0,23.4)	26.9 (25.8,28.2)	33.2 (31.6,35.8)**
Resistance	488.5 (440.0,548.0)	644.0 (604.0,695.0)	510.0 (473.0,562.0)	463.0 (423.0,506.0)	423.5 (390.0,482.0)**
Reactance	57.0 (51.0,63.0)	63.5 (52.0,70.0)	59.0 (54.0,65.0)	56.0 (51.0,61.0)	52.0 (47.0,57.0)**
Phase Angle	6.7 (6.0,7.3)	5.5 (4.6,6.2)	6.5 (5.9,7.1)	6.9 (6.3,7.5)	6.9 (6.3,7.6)**
Fat Mass %	23.9 (18.1,30.1)	15.7 (12.5,19.4)	20.3 (16.0,24.8)	25.6 (22.0,31.3)	33.2 (27.9,42.4)**
Fat Free Mass %	76.1 (69.9,81.9)	84.3 (80.6,87.5)	79.7 (75.2,84.0)	74.4 (68.7,78.0)	66.8 (57.6,72.1)**
<i>At time of last BIA:^b</i>					
Height (cm)	175.3 (170.2,182.9)	175.3 (166.4,180.3)	176.5 (170.2,182.9)	177.8 (170.2,182.9)	175.3 (165.1,180.3)**
Weight (kg)	77.3 (66.8,90.9)	51.4 (45.0,55.9)	68.6 (62.7,74.1)	84.5 (79.1,90.9)	106.1 (95.5,117.3)**
Body mass index	25.0 (21.6,28.8)	17.1 (15.8,17.9)	22.0 (20.8,23.5)	27.0 (26.0,28.2)	33.5 (31.5,38.2)**
Resistance	487.5 (436.0,547.0)	646.0 (556.0,709.0)	511.0 (475.0,566.0)	465.5 (429.0,518.0)	425.0 (388.0,459.0)**
Reactance	53.0 (47.0,59.0)	52.0 (44.0,59.0)	55.0 (49.0,60.0)	53.0 (48.0,59.0)	49.0 (44.0,54.0)**
Phase Angle	6.2 (5.5,6.9)	4.7 (3.7,5.6)	6.1 (5.4,6.7)	6.4 (5.9,7.1)	6.5 (5.8,7.3)**
Fat Mass %	24.3 (18.6,30.7)	12.8 (9.3,19.1)	20.1 (15.9,25.2)	26.8 (22.1,31.6)	33.4 (28.3,42.7)**
Fat Free Mass %	75.7 (69.3,81.4)	87.2 (80.9,90.7)	80.0 (74.8,84.1)	73.2 (68.4,77.9)	66.6 (57.3,71.7)**

* = Kruskal-Wallis test $p < .05$ ** = Kruskal-Wallis test $p < .01$ ^aBMI categories for the “At time of highest BIA” values are based on the BMI at time of highest BIA^bBMI categories for the “At time of last BIA” values are based on the BMI at time of last BIA

Table 3.

Demographic and clinical characteristics associated with mortality by BMI category in separate logistic regression models

	Total Sample N = 890 (102 deaths)	Underweight (BMI < 18.5) n = 50 (13 deaths)	Normal Weight (BMI 18.5-24.9) n = 409 (62 deaths)	Overweight (BMI 25-29.8) n = 261 (18 deaths)	Obesity (BMI ≥ 30) n = 170 (9 deaths)
Univariate models					
BIA-PA change (per 1 unit decrease)	1.8 (1.5, 2.2) **	5.8 (1.8, 19.0) **	2.2 (1.6, 3.1) **	1.3 (0.9, 2.0)	0.9 (0.4, 2.2)
Multivariate models					
BIA-PA change (per 1 unit decrease)	2.2 (1.6, 2.9) **	6.6 (1.2, 34.8) *	2.2 (1.5, 3.4) **	1.7 (0.9, 3.2)	0.9 (0.3, 3.0)
BIA-PA (highest)	0.6 (0.4, 0.7) **	0.5 (0.1, 1.5)	0.6 (0.4, 0.8) **	0.6 (0.3, 0.9) **	0.9 (0.4, 1.8)
Insurance Type:					
<i>Private</i>	Referent	referent	referent	referent	referent
<i>Public</i>	2.7 (1.5, 5.1) **	1.2 (0.1, 30.3)	2.8 (1.2, 6.4) *	2.2 (0.5, 9.5)	6.3 (0.8, 52.5)
<i>None</i>	1.2 (0.5, 2.6)	1.3 (0.1, 60.3)	0.8 (0.3, 2.3)	2.1 (0.4, 9.9)	0.1 (0.1, 100.0)
CDC "C" Diagnosis	1.9 (1.1, 3.2) *	3.8 (0.3, 46.3)	2.4 (1.1, 5.2) *	0.9 (0.3, 2.7)	1.9 (0.3, 12.0)
Protease Inhibitor (ever)	1.7 (0.9, 3.1)	1.0 (0.2, 8.1)	1.3 (0.6, 3.1)	1.8 (0.5, 6.4)	2.3 (0.2, 24.1)
CD4+ (at highest BIA)					
>350	referent	referent	referent	referent	referent
200-350	1.5 (0.7, 3.4)	5.2 (0.2, 176.0)	1.4 (0.5, 4.1)	1.9 (0.3, 10.9)	0.1 (0.1, 100.0)
<200	4.3 (2.2, 8.3) **	1.9 (0.1, 29.8)	4.5 (1.8, 10.9) **	5.8 (1.3, 26.5) *	7.8 (1.0, 71.6) *
CD4+ change (per 50 cell increase) ^a	0.9 (0.8, 0.9) **	1.0 (0.7, 1.3)	0.8 (0.7, 0.9) **	0.9 (0.8, 1.0)	0.8 (0.6, 1.0)

* : $p < .05$ ** : $p < .01$ ^a = change between highest and last BIA-PA measurements

BMI = body mass index; BIA-PA = bioelectrical impedance analysis phase angle; CDC = Centers for Disease Control and Prevention